Acorda responds to first Bass challenge

Acorda Therapeutics Inc. (NASDAQ:ACOR) responded to an inter partes review (IPR) filed by hedge fund manager Kyle Bass in February against U.S. Patent No. 8,633,685, a methods patent covering multiple sclerosis drug Ampyra dalfampridine.

The patent, which expires in 2025, is one of five Orange Book-listed patents for the sustained-release formulation of 4-aminopyridine (4-AP). Bass filed another IPR in February challenging Acorda's U.S. Patent No. 8,007,826, which covers Ampyra and expires in 2027. Acorda intends to file its response to the second IPR by June 19. ...